Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial
Our objective was to determine the number of major cardiovascular events (MACE, nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) and deaths from any cause that could be prevented across varying nationwide uptake of semaglutide 2.4 mg SC weekly for the secondary prevention of...
Gespeichert in:
Veröffentlicht in: | The American heart journal 2024-10, Vol.276, p.110-114 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 114 |
---|---|
container_issue | |
container_start_page | 110 |
container_title | The American heart journal |
container_volume | 276 |
creator | Lusk, Jay B. Glover, LáShauntá Soneji, Samir Granger, Christopher B. O'Brien, Emily Pagidipati, Neha |
description | Our objective was to determine the number of major cardiovascular events (MACE, nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) and deaths from any cause that could be prevented across varying nationwide uptake of semaglutide 2.4 mg SC weekly for the secondary prevention of cardiovascular disease.
Using a nationally representative cross-sectional study of participants in the 2017-2018 and 2019-March 2020 cycles of the National Health and Nutrition Examination Survey in the U.S. (NHANES), we estimated the number of MACE and deaths from any cause potentially prevented over a four-year period among participants meeting SELECT trial inclusion criteria.
In a sample of n = 216 individuals (corresponding to 4,473,681 adults in the U.S. population) potentially eligible for this therapy, a total of 356,329 MACE and 232,808 all-cause mortality events were expected without semaglutide over 4 years and 35,633 MACE and 22,117 all-cause mortality events would be prevented with 50% uptake of semaglutide.
Approximately 4.5 million adults in the U.S. are forecasted to be eligible for semaglutide 2.4mg SC weekly therapy, with substantial impact on CVD and mortality if accessible and broadly used. |
doi_str_mv | 10.1016/j.ahj.2024.05.007 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3097148681</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002870324001224</els_id><sourcerecordid>3096044932</sourcerecordid><originalsourceid>FETCH-LOGICAL-c263t-871df9b0222a9f3701fb944986181decd45bcdcaa93c757e22a35b847bae354c3</originalsourceid><addsrcrecordid>eNp9kctO5DAQRa0Ro6Fh5gPYIEts2HTGrzwsVqjVPKSWZgGsLceuNI6SONhJS_w97mlgwYJVqUqnbpXuReiMkowSWvxtM_3cZowwkZE8I6T8gRaUyHJZlEIcoQUhhC2rkvBjdBJjm9qCVcUvdMwlrZjkcoHqlQ7W-Z2OZu50wLCDYcIB7Gwm5wesez9sscZPD3j0Y0L-T6FzW1d3gBsfcIReb7t5chbwCAFPz4Af1pv16hFPwenuN_rZ6C7Cn_d6ip5u1o-ru-Xm3-396nqzNKzgU_qT2kbWhDGmZcNLQptaCiGrglbUgrEir401WktuyryEhPG8rkRZa-C5MPwUXR50x-BfZoiT6l000HV6AD9HxZMzVFRFRRN68QVt_RyG9N2eKkg6y1mi6IEywccYoFFjcL0Or4oStQ9AtSoFoPYBKJKrFEDaOX9Xnuse7OfGh-MJuDoAkKzYOQgqGgeDAesCmElZ776RfwOr55V6</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3096044932</pqid></control><display><type>article</type><title>Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Lusk, Jay B. ; Glover, LáShauntá ; Soneji, Samir ; Granger, Christopher B. ; O'Brien, Emily ; Pagidipati, Neha</creator><creatorcontrib>Lusk, Jay B. ; Glover, LáShauntá ; Soneji, Samir ; Granger, Christopher B. ; O'Brien, Emily ; Pagidipati, Neha</creatorcontrib><description>Our objective was to determine the number of major cardiovascular events (MACE, nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) and deaths from any cause that could be prevented across varying nationwide uptake of semaglutide 2.4 mg SC weekly for the secondary prevention of cardiovascular disease.
Using a nationally representative cross-sectional study of participants in the 2017-2018 and 2019-March 2020 cycles of the National Health and Nutrition Examination Survey in the U.S. (NHANES), we estimated the number of MACE and deaths from any cause potentially prevented over a four-year period among participants meeting SELECT trial inclusion criteria.
In a sample of n = 216 individuals (corresponding to 4,473,681 adults in the U.S. population) potentially eligible for this therapy, a total of 356,329 MACE and 232,808 all-cause mortality events were expected without semaglutide over 4 years and 35,633 MACE and 22,117 all-cause mortality events would be prevented with 50% uptake of semaglutide.
Approximately 4.5 million adults in the U.S. are forecasted to be eligible for semaglutide 2.4mg SC weekly therapy, with substantial impact on CVD and mortality if accessible and broadly used.</description><identifier>ISSN: 0002-8703</identifier><identifier>ISSN: 1097-6744</identifier><identifier>EISSN: 1097-6744</identifier><identifier>DOI: 10.1016/j.ahj.2024.05.007</identifier><identifier>PMID: 39182939</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Adults ; Aged ; Body mass index ; Cardiovascular diseases ; Cardiovascular Diseases - epidemiology ; Cardiovascular Diseases - mortality ; Cardiovascular Diseases - prevention & control ; Cerebral infarction ; Cross-Sectional Studies ; Diabetes ; Drug dosages ; Editing ; Estimates ; Fatalities ; Female ; Glucagon-Like Peptides - administration & dosage ; Glucagon-Like Peptides - therapeutic use ; Humans ; Hypoglycemic Agents - therapeutic use ; Male ; Medicare ; Middle Aged ; Mortality ; Myocardial infarction ; Myocardial Infarction - epidemiology ; Myocardial Infarction - prevention & control ; Nutrition Surveys ; Obesity ; Pharmaceuticals ; Secondary Prevention - methods ; Stroke ; Stroke - epidemiology ; Stroke - prevention & control ; United States - epidemiology</subject><ispartof>The American heart journal, 2024-10, Vol.276, p.110-114</ispartof><rights>2024 Elsevier Inc.</rights><rights>Copyright © 2024 Elsevier Inc. All rights reserved.</rights><rights>2024. Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c263t-871df9b0222a9f3701fb944986181decd45bcdcaa93c757e22a35b847bae354c3</cites><orcidid>0000-0002-5004-8868</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/3096044932?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>315,781,785,3551,27929,27930,46000,64390,64392,64394,72474</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39182939$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lusk, Jay B.</creatorcontrib><creatorcontrib>Glover, LáShauntá</creatorcontrib><creatorcontrib>Soneji, Samir</creatorcontrib><creatorcontrib>Granger, Christopher B.</creatorcontrib><creatorcontrib>O'Brien, Emily</creatorcontrib><creatorcontrib>Pagidipati, Neha</creatorcontrib><title>Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial</title><title>The American heart journal</title><addtitle>Am Heart J</addtitle><description>Our objective was to determine the number of major cardiovascular events (MACE, nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) and deaths from any cause that could be prevented across varying nationwide uptake of semaglutide 2.4 mg SC weekly for the secondary prevention of cardiovascular disease.
Using a nationally representative cross-sectional study of participants in the 2017-2018 and 2019-March 2020 cycles of the National Health and Nutrition Examination Survey in the U.S. (NHANES), we estimated the number of MACE and deaths from any cause potentially prevented over a four-year period among participants meeting SELECT trial inclusion criteria.
In a sample of n = 216 individuals (corresponding to 4,473,681 adults in the U.S. population) potentially eligible for this therapy, a total of 356,329 MACE and 232,808 all-cause mortality events were expected without semaglutide over 4 years and 35,633 MACE and 22,117 all-cause mortality events would be prevented with 50% uptake of semaglutide.
Approximately 4.5 million adults in the U.S. are forecasted to be eligible for semaglutide 2.4mg SC weekly therapy, with substantial impact on CVD and mortality if accessible and broadly used.</description><subject>Adult</subject><subject>Adults</subject><subject>Aged</subject><subject>Body mass index</subject><subject>Cardiovascular diseases</subject><subject>Cardiovascular Diseases - epidemiology</subject><subject>Cardiovascular Diseases - mortality</subject><subject>Cardiovascular Diseases - prevention & control</subject><subject>Cerebral infarction</subject><subject>Cross-Sectional Studies</subject><subject>Diabetes</subject><subject>Drug dosages</subject><subject>Editing</subject><subject>Estimates</subject><subject>Fatalities</subject><subject>Female</subject><subject>Glucagon-Like Peptides - administration & dosage</subject><subject>Glucagon-Like Peptides - therapeutic use</subject><subject>Humans</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Male</subject><subject>Medicare</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Myocardial infarction</subject><subject>Myocardial Infarction - epidemiology</subject><subject>Myocardial Infarction - prevention & control</subject><subject>Nutrition Surveys</subject><subject>Obesity</subject><subject>Pharmaceuticals</subject><subject>Secondary Prevention - methods</subject><subject>Stroke</subject><subject>Stroke - epidemiology</subject><subject>Stroke - prevention & control</subject><subject>United States - epidemiology</subject><issn>0002-8703</issn><issn>1097-6744</issn><issn>1097-6744</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kctO5DAQRa0Ro6Fh5gPYIEts2HTGrzwsVqjVPKSWZgGsLceuNI6SONhJS_w97mlgwYJVqUqnbpXuReiMkowSWvxtM_3cZowwkZE8I6T8gRaUyHJZlEIcoQUhhC2rkvBjdBJjm9qCVcUvdMwlrZjkcoHqlQ7W-Z2OZu50wLCDYcIB7Gwm5wesez9sscZPD3j0Y0L-T6FzW1d3gBsfcIReb7t5chbwCAFPz4Af1pv16hFPwenuN_rZ6C7Cn_d6ip5u1o-ru-Xm3-396nqzNKzgU_qT2kbWhDGmZcNLQptaCiGrglbUgrEir401WktuyryEhPG8rkRZa-C5MPwUXR50x-BfZoiT6l000HV6AD9HxZMzVFRFRRN68QVt_RyG9N2eKkg6y1mi6IEywccYoFFjcL0Or4oStQ9AtSoFoPYBKJKrFEDaOX9Xnuse7OfGh-MJuDoAkKzYOQgqGgeDAesCmElZ776RfwOr55V6</recordid><startdate>202410</startdate><enddate>202410</enddate><creator>Lusk, Jay B.</creator><creator>Glover, LáShauntá</creator><creator>Soneji, Samir</creator><creator>Granger, Christopher B.</creator><creator>O'Brien, Emily</creator><creator>Pagidipati, Neha</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5004-8868</orcidid></search><sort><creationdate>202410</creationdate><title>Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial</title><author>Lusk, Jay B. ; Glover, LáShauntá ; Soneji, Samir ; Granger, Christopher B. ; O'Brien, Emily ; Pagidipati, Neha</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c263t-871df9b0222a9f3701fb944986181decd45bcdcaa93c757e22a35b847bae354c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Adults</topic><topic>Aged</topic><topic>Body mass index</topic><topic>Cardiovascular diseases</topic><topic>Cardiovascular Diseases - epidemiology</topic><topic>Cardiovascular Diseases - mortality</topic><topic>Cardiovascular Diseases - prevention & control</topic><topic>Cerebral infarction</topic><topic>Cross-Sectional Studies</topic><topic>Diabetes</topic><topic>Drug dosages</topic><topic>Editing</topic><topic>Estimates</topic><topic>Fatalities</topic><topic>Female</topic><topic>Glucagon-Like Peptides - administration & dosage</topic><topic>Glucagon-Like Peptides - therapeutic use</topic><topic>Humans</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Male</topic><topic>Medicare</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Myocardial infarction</topic><topic>Myocardial Infarction - epidemiology</topic><topic>Myocardial Infarction - prevention & control</topic><topic>Nutrition Surveys</topic><topic>Obesity</topic><topic>Pharmaceuticals</topic><topic>Secondary Prevention - methods</topic><topic>Stroke</topic><topic>Stroke - epidemiology</topic><topic>Stroke - prevention & control</topic><topic>United States - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lusk, Jay B.</creatorcontrib><creatorcontrib>Glover, LáShauntá</creatorcontrib><creatorcontrib>Soneji, Samir</creatorcontrib><creatorcontrib>Granger, Christopher B.</creatorcontrib><creatorcontrib>O'Brien, Emily</creatorcontrib><creatorcontrib>Pagidipati, Neha</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The American heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lusk, Jay B.</au><au>Glover, LáShauntá</au><au>Soneji, Samir</au><au>Granger, Christopher B.</au><au>O'Brien, Emily</au><au>Pagidipati, Neha</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial</atitle><jtitle>The American heart journal</jtitle><addtitle>Am Heart J</addtitle><date>2024-10</date><risdate>2024</risdate><volume>276</volume><spage>110</spage><epage>114</epage><pages>110-114</pages><issn>0002-8703</issn><issn>1097-6744</issn><eissn>1097-6744</eissn><abstract>Our objective was to determine the number of major cardiovascular events (MACE, nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) and deaths from any cause that could be prevented across varying nationwide uptake of semaglutide 2.4 mg SC weekly for the secondary prevention of cardiovascular disease.
Using a nationally representative cross-sectional study of participants in the 2017-2018 and 2019-March 2020 cycles of the National Health and Nutrition Examination Survey in the U.S. (NHANES), we estimated the number of MACE and deaths from any cause potentially prevented over a four-year period among participants meeting SELECT trial inclusion criteria.
In a sample of n = 216 individuals (corresponding to 4,473,681 adults in the U.S. population) potentially eligible for this therapy, a total of 356,329 MACE and 232,808 all-cause mortality events were expected without semaglutide over 4 years and 35,633 MACE and 22,117 all-cause mortality events would be prevented with 50% uptake of semaglutide.
Approximately 4.5 million adults in the U.S. are forecasted to be eligible for semaglutide 2.4mg SC weekly therapy, with substantial impact on CVD and mortality if accessible and broadly used.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>39182939</pmid><doi>10.1016/j.ahj.2024.05.007</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-5004-8868</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0002-8703 |
ispartof | The American heart journal, 2024-10, Vol.276, p.110-114 |
issn | 0002-8703 1097-6744 1097-6744 |
language | eng |
recordid | cdi_proquest_miscellaneous_3097148681 |
source | MEDLINE; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
subjects | Adult Adults Aged Body mass index Cardiovascular diseases Cardiovascular Diseases - epidemiology Cardiovascular Diseases - mortality Cardiovascular Diseases - prevention & control Cerebral infarction Cross-Sectional Studies Diabetes Drug dosages Editing Estimates Fatalities Female Glucagon-Like Peptides - administration & dosage Glucagon-Like Peptides - therapeutic use Humans Hypoglycemic Agents - therapeutic use Male Medicare Middle Aged Mortality Myocardial infarction Myocardial Infarction - epidemiology Myocardial Infarction - prevention & control Nutrition Surveys Obesity Pharmaceuticals Secondary Prevention - methods Stroke Stroke - epidemiology Stroke - prevention & control United States - epidemiology |
title | Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T21%3A15%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cardiovascular%20event%20reduction%20among%20a%20US%20population%20eligible%20for%20semaglutide%20per%20the%20SELECT%20trial&rft.jtitle=The%20American%20heart%20journal&rft.au=Lusk,%20Jay%20B.&rft.date=2024-10&rft.volume=276&rft.spage=110&rft.epage=114&rft.pages=110-114&rft.issn=0002-8703&rft.eissn=1097-6744&rft_id=info:doi/10.1016/j.ahj.2024.05.007&rft_dat=%3Cproquest_cross%3E3096044932%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3096044932&rft_id=info:pmid/39182939&rft_els_id=S0002870324001224&rfr_iscdi=true |